ARCH Venture Fund X Overage, L.P.

ARCH Venture Fund X Overage, L.P. insider trades: Aspen Neuroscience (ASPE) stock buys and sales

Aspen Neuroscience Last trade Nov 2, 2026 14 Form 4 filings
$40K
Sold, last 12 months
1 sale
$20.0M
Bought, last 12 months
2 buys
12
Open-market trades
since 2019
8
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where ARCH Venture Fund X Overage, L.P. reports to the SEC

and 2 more companies

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 2, 2026ASPE↑ Buy$18.0M
Nov 2, 2026ASPE↑ Buy$2.0M
Jul 1, 2026BOLD↓ Sell$40K
Oct 27, 2025NMRA↑ Buy$5.0M
Aug 1, 2025PRME↑ Buy$10.0M
Apr 2, 2024BOLD↑ Buy$3.2M
Feb 15, 2024PRME↑ Buy$20.0M
Feb 8, 2024SANA↑ Buy$6.0M
Sep 19, 2023NMRA↑ Buy$25.5M
Oct 24, 2022PRME↑ Buy$6.8M
Oct 24, 2022PRME↑ Buy$6.8M
Feb 22, 2019SNNA↑ Buy$5.4M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ASPE insiders

Open-market trades in the last 12 months

About ARCH Venture Fund X Overage, L.P.'s insider trades

ARCH Venture Fund X Overage, L.P. is an insider at Aspen Neuroscience (ASPE). Since Feb 22, 2019, it has reported 11 open-market purchases worth $108.7M and 1 sale worth $40K on SEC Form 4. In the last 12 months: 2 buys ($20.0M) and 1 sale ($40K).

Its filings also include conversions (7 filings), option exercises (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ASPE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.